SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma
Xian-De Liu(The University of Texas MD Anderson Cancer Center), Eric Jonasch(The University of Texas MD Anderson Cancer Center)
Cited by 13
Related Papers
PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma
|Nature Communications|2020|173